Related Blog Posts
After Four Years on DuraHeart Device, Patient Receives Heart Transplant
4 hours ago ago from bloglongtermcare.com
Terumo Heart, Inc., has announced that one of its earliest patients to receive the DuraHeart™ Left Ventricular Assist System (LVAS) has received a donor heart transplant, nearly four years after receiving the mechanical circulatory support device. Rudolf Schmidthorst, 63, of Germany, became one of the longest-living recipients of this device designed to aid the pumping action of the heart in order to circulate blood throughout his body. “I am ...
Related contentDoes Dartmouth Study Distort Health Spending Data?
11 hours ago ago from Laura Hershey: Writer, Poet, Activist, Consultant
In the ongoing health care debate, it seems that we hear more frequently about patients costing too much money, rather than about the vast amounts being hoarded by the profit-hungry corporate insurance system and/or wasted by senseless decisions in both the private and public sector. A current article in the New York Times describes the findings of a study conducted by Dartmouth health policy researchers, which criticizes hospitals that ...
Related contentMesothelioma Researchers Study Another Biological Marker and Its Role in Patient Prognosis Medical News
12 hours ago ago from Medical News
Posted by mwhitmer | 10 December 2009, 3:30 pm French researchers have found another biological marker associated with the prognosis of malignant mesothelioma. Identifying this prognostic marker and investigating it further could lead to a better understanding of mesothelioma prognosis factors and what they mean for mesothelioma patients. The biological marker is neurotensin (NTS) and its cognate receptor (NTSR1). Neurotensin is ...
Related contentAbdominal Surgery Higher Risk for Seniors
17 hours ago ago from Blisstree
Any type of surgery has its risks, even so-called minor surgeries. But some surgeries are riskier than others and even more so for certain groups of people. Seniors, those aged 65 years or older, often undergo surgery for various ailments that have either been neglected over time or have developed over the years. And, as the population ages, more surgeries will be done in that age group. According to a study jus t published in the ...
Related contentpSivida Shares Boom as Eye Drug Passes Pivotal Trial
14 hours ago ago from Xconomy
Biotech , diabetes , Eye Disorders Luke Timmerman wrote: Shares of pSivida (NASDAQ: PSDV ) rocketed more than 50 percent this morning on some positive clinical trial news. The Watertown, MA-based company, the developer of a treatment for an eye disorder related to diabetes, said its technology helped patients improve their vision after two years of follow up in a clinical trial. pSivida climbed 56 percent to $5.49 at 10:37 am Eastern ...
Related contentRelated News
Nothing to see... move along.
Related Videos
Nothing to see... move along.
